![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 4 of 4. This is the beginning of the thread.
Posted by Lamdage22 on February 19, 2020, at 11:32:35
Posted by Jadde on February 19, 2020, at 15:01:22
In reply to Overview of Pipeline as of 2019, posted by Lamdage22 on February 19, 2020, at 11:32:35
Wow, thats a nice long list! Anything there we should be super excited about, in particular? I thought Nardil would be my lifelong med, but no :(
Thanks,
Jade
Posted by undopaminergic on February 20, 2020, at 3:47:34
In reply to Re: Overview of Pipeline as of 2019 » Lamdage22, posted by Jadde on February 19, 2020, at 15:01:22
> > https://www.phrma.org/-/media/Project/PhRMA/PhRMA-Org/PhRMA-Org/PDF/MID_Mental-Illness-2019-Drug-List_Final.pdf
>
> Wow, thats a nice long list! Anything there we should be super excited about, in particular?
>Especially the kappa-opioid receptor antagonists, in particular because these would be the first in their class to be approved/marketed.
The reuptake inhibitors that act on dopamine are also of some interest, although we already have methylphenidate.
-undopaminergic
Posted by Lamdage22 on February 20, 2020, at 5:46:27
In reply to Re: Overview of Pipeline as of 2019, posted by undopaminergic on February 20, 2020, at 3:47:34
I am excited about Aloradine because I have social anxiety.
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.